The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant promise in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a greater substantial reduction in body size and improve metabolic function, particularl